Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immuneering CorpIMRX · Entity 5884 | Director | June 11, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immuneering Corp
Report date June 11, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.12 · Expires 2036-06-11 | Direct | 33,350 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 33,350 · Balance 33,350 F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ChemoCentryx, Inc.
Report date October 20, 2022 · Filed October 24, 2022
Section 16 reporting ended · disclosed 2022-10-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 1
1 source rowRow 1 · 2022-10-20 · Disposition to issuer · Disposed 2,393,352 · Balance 0 F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised, F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $29.83 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-20 · Disposition to issuer · Disposed 4,192 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $29.83 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-20 · Disposition to issuer · Disposed 188,408 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $46.59 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-20 · Disposition to issuer · Disposed 2,502 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $46.59 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-20 · Disposition to issuer · Disposed 68,998 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $11.02 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-20 · Disposition to issuer · Disposed 7,912 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $11.02 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-20 · Disposition to issuer · Disposed 222,088 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.86 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-10-20 · Disposition to issuer · Disposed 11,693 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.86 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-10-20 · Disposition to issuer · Disposed 278,307 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.62 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-10-20 · Disposition to issuer · Disposed 262,431 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.62 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-10-20 · Disposition to issuer · Disposed 17,569 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.57 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-10-20 · Disposition to issuer · Disposed 285,812 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.57 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2022-10-20 · Disposition to issuer · Disposed 14,188 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.19 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2022-10-20 · Disposition to issuer · Disposed 406,175 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.19 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2022-10-20 · Disposition to issuer · Disposed 13,825 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.10 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2022-10-20 · Disposition to issuer · Disposed 8,231 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.10 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2022-10-20 · Disposition to issuer · Disposed 386,769 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.28 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2022-10-20 · Disposition to issuer · Disposed 7,002 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.28 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2022-10-20 · Disposition to issuer · Disposed 27,998 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2022-10-20 · Disposition to issuer · Disposed 239,934 · Balance 0 F4: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised,
F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.
F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
F4: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2021 Filed Jan 8, 2021 01:40 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 34,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002636 · doc4.xml · nonDerivative · entry 3 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,356,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Shares were acquired upon vesting of restricted stock units awarded on March 3, 2020. Read SEC document |
| January 01, 2021 Filed Jan 8, 2021 01:40 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 23,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002636 · doc4.xml · nonDerivative · entry 2 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,321,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Shares were acquired upon vesting of restricted stock units awarded on March 4, 2019. Read SEC document |
| January 01, 2021 Filed Jan 8, 2021 01:40 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002636 · doc4.xml · nonDerivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,298,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares were acquired upon vesting of restricted stock units awarded on March 5, 2018. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 00:51 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionStock Option (right to buy) · Derivative | 17,619 | Not disclosed Strike: $14.31 | Not disclosed |
DisclosureSEC source: 0001209191-20-063919 · doc4.xml · derivative · entry 6 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,988 Underlying: Common Stock · 17,619 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: As of December 14, 2020, and prior to this transaction, the exercised options were fully vested. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 00:51 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 17,619 | $65.01 | $1,145,449.95 |
DisclosureSEC source: 0001209191-20-063919 · doc4.xml · nonDerivative · entry 4 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268,557 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $64.99 to $65.16 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 00:51 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 17,619 | $14.31 | $252,127.89 |
DisclosureSEC source: 0001209191-20-063919 · doc4.xml · nonDerivative · entry 3 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,286,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2020 Filed Dec 17, 2020 00:51 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionStock Option (right to buy) · Derivative | 11,153 | Not disclosed Strike: $14.31 | Not disclosed |
DisclosureSEC source: 0001209191-20-063919 · doc4.xml · derivative · entry 5 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,607 Underlying: Common Stock · 11,153 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: As of December 14, 2020, and prior to this transaction, the exercised options were fully vested. Read SEC document |
| December 14, 2020 Filed Dec 17, 2020 00:51 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 11,153 | $65.03 | $725,246.13 |
DisclosureSEC source: 0001209191-20-063919 · doc4.xml · nonDerivative · entry 2 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268,557 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $64.99 to $65.20 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 14, 2020 Filed Dec 17, 2020 00:51 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 11,153 | $14.31 | $159,599.43 |
DisclosureSEC source: 0001209191-20-063919 · doc4.xml · nonDerivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,279,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 00:20 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | Not disclosed Strike: $14.31 | Not disclosed |
DisclosureSEC source: 0001209191-20-037135 · doc4.xml · derivative · entry 6 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,760 Underlying: Common Stock · 2,000 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: As of June 12, 2020, and prior to this transaction, the exercised options were fully vested. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 00:20 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 2,000 | $65.04 | $130,089.60 |
DisclosureSEC source: 0001209191-20-037135 · doc4.xml · nonDerivative · entry 4 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268,557 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $64.99 to $65.22 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 00:20 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 2,000 | $14.31 | $28,620.00 |
DisclosureSEC source: 0001209191-20-037135 · doc4.xml · nonDerivative · entry 3 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,270,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2020 Filed Jun 17, 2020 00:20 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionStock Option (right to buy) · Derivative | 88,753 | Not disclosed Strike: $14.31 | Not disclosed |
DisclosureSEC source: 0001209191-20-037135 · doc4.xml · derivative · entry 5 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,760 Underlying: Common Stock · 88,753 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: As of June 12, 2020, and prior to this transaction, the exercised options were fully vested. Read SEC document |
| June 12, 2020 Filed Jun 17, 2020 00:20 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 88,753 | $65.08 | $5,775,876.61 |
DisclosureSEC source: 0001209191-20-037135 · doc4.xml · nonDerivative · entry 2 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268,557 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $64.99 to $65.39 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 12, 2020 Filed Jun 17, 2020 00:20 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 88,753 | $14.31 | $1,270,055.43 |
DisclosureSEC source: 0001209191-20-037135 · doc4.xml · nonDerivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,357,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 12, 2020 23:50 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionStock Option (right to buy) · Derivative | 35,865 | Not disclosed Strike: $14.31 | Not disclosed |
DisclosureSEC source: 0001209191-20-028669 · doc4.xml · derivative · entry 10 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,513 Underlying: Common Stock · 35,865 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: As of May 8, 2020, and prior to this transaction, the exercised options were fully vested. Read SEC document |
| May 12, 2020 Filed May 12, 2020 23:50 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 35,865 | $57.75 | $2,071,099.74 |
DisclosureSEC source: 0001209191-20-028669 · doc4.xml · nonDerivative · entry 7 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268,557 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 12, 2020 Filed May 12, 2020 23:50 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 35,865 | $14.31 | $513,228.15 |
DisclosureSEC source: 0001209191-20-028669 · doc4.xml · nonDerivative · entry 6 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,304,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 12, 2020 23:50 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionStock Option (right to buy) · Derivative | 70,608 | Not disclosed Strike: $14.31 | Not disclosed |
DisclosureSEC source: 0001209191-20-028669 · doc4.xml · derivative · entry 9 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,378 Underlying: Common Stock · 70,608 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: As of May 8, 2020, and prior to this transaction, the exercised options were fully vested. Read SEC document |
| May 11, 2020 Filed May 12, 2020 23:50 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 16,029 | $56.14 | $899,874.47 |
DisclosureSEC source: 0001209191-20-028669 · doc4.xml · nonDerivative · entry 5 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268,557 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $56.00 to $56.39 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 11, 2020 Filed May 12, 2020 23:50 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 54,579 | $55.33 | $3,019,856.07 |
DisclosureSEC source: 0001209191-20-028669 · doc4.xml · nonDerivative · entry 4 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,284,586 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $54.99 to $55.98 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 11, 2020 Filed May 12, 2020 23:50 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 70,608 | $14.31 | $1,010,400.48 |
DisclosureSEC source: 0001209191-20-028669 · doc4.xml · nonDerivative · entry 3 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,339,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2020 Filed May 12, 2020 23:50 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionStock Option (right to buy) · Derivative | 4,201 | Not disclosed Strike: $14.31 | Not disclosed |
DisclosureSEC source: 0001209191-20-028669 · doc4.xml · derivative · entry 8 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,986 Underlying: Common Stock · 4,201 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: As of May 8, 2020, and prior to this transaction, the exercised options were fully vested. Read SEC document |
| May 08, 2020 Filed May 12, 2020 23:50 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 4,201 | $55.01 | $231,114.65 |
DisclosureSEC source: 0001209191-20-028669 · doc4.xml · nonDerivative · entry 2 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268,557 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $54.99 to $55.09 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 08, 2020 Filed May 12, 2020 23:50 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 4,201 | $14.31 | $60,116.31 |
DisclosureSEC source: 0001209191-20-028669 · doc4.xml · nonDerivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,272,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 8, 2020 00:11 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionStock Option (right to buy) · Derivative | 8,851 | Not disclosed Strike: $14.31 | Not disclosed |
DisclosureSEC source: 0001209191-20-027817 · doc4.xml · derivative · entry 3 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,187 Underlying: Common Stock · 8,851 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: As of May 5, 2020, and prior to this transaction, the exercised options were fully vested. Read SEC document |
| May 05, 2020 Filed May 8, 2020 00:11 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 8,851 | $55.01 | $486,851.03 |
DisclosureSEC source: 0001209191-20-027817 · doc4.xml · nonDerivative · entry 2 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268,557 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $54.99 to $55.09 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 05, 2020 Filed May 8, 2020 00:11 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 8,851 | $14.31 | $126,657.81 |
DisclosureSEC source: 0001209191-20-027817 · doc4.xml · nonDerivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,277,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 00:03 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionStock Option (right to buy) · Derivative | 40,844 | Not disclosed Strike: $14.31 | Not disclosed |
DisclosureSEC source: 0001209191-20-016765 · doc4.xml · derivative · entry 3 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,038 Underlying: Common Stock · 40,844 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: As of March 4, 2020, and prior to this transaction, the exercised options were fully vested. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 00:03 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 40,844 | $50.35 | $2,056,691.45 |
DisclosureSEC source: 0001209191-20-016765 · doc4.xml · nonDerivative · entry 2 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268,557 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $49.99 to $50.83 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 00:03 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 40,844 | $14.31 | $584,477.64 |
DisclosureSEC source: 0001209191-20-016765 · doc4.xml · nonDerivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,309,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2020 Filed Mar 6, 2020 00:03 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantStock Option (right to buy) · Derivative | 71,500 | Not disclosed Strike: $46.59 | Not disclosed |
DisclosureSEC source: 0001209191-20-016765 · doc4.xml · derivative · entry 5 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,500 Underlying: Common Stock · 71,500 shares Expires 2030-03-03 F4 · price: Not applicable. F7 · derivative.exercise_date: The option was granted on March 3, 2020, and 25% of the total number of shares of common stock subject to the option vests on January 1, 2021, and 1/48th of the total number of shares of common stock subject to the option vests monthly thereafter, subject to the Reporting Person's continued service to the Company on each such vesting date. Read SEC document |
| March 03, 2020 Filed Mar 6, 2020 00:03 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantRestricted Stock Units · Derivative | 103,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-016765 · doc4.xml · derivative · entry 4 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,700 Underlying: Common Stock · 103,700 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F5 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F6 · derivative.exercise_date: The restricted stock units awarded on March 3, 2020, vest in three equal installments on January 1, 2021, January 1, 2022, and January 1, 2023, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. F6 · derivative.expiration_date: The restricted stock units awarded on March 3, 2020, vest in three equal installments on January 1, 2021, January 1, 2022, and January 1, 2023, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document |
| February 20, 2020 Filed Feb 22, 2020 00:24 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionStock Option (right to buy) · Derivative | 15,341 | Not disclosed Strike: $14.31 | Not disclosed |
DisclosureSEC source: 0001209191-20-011796 · doc4.xml · derivative · entry 8 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,882 Underlying: Common Stock · 15,341 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: As of February 19, 2020, and prior to this transaction, the exercised options were fully vested. Read SEC document |
| February 20, 2020 Filed Feb 22, 2020 00:24 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 29 | $51.10 | $1,481.90 |
DisclosureSEC source: 0001209191-20-011796 · doc4.xml · nonDerivative · entry 6 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268,557 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 20, 2020 Filed Feb 22, 2020 00:24 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 15,312 | $50.21 | $768,813.99 |
DisclosureSEC source: 0001209191-20-011796 · doc4.xml · nonDerivative · entry 5 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268,586 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $49.99 to $50.92 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 20, 2020 Filed Feb 22, 2020 00:24 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 15,341 | $14.31 | $219,529.71 |
DisclosureSEC source: 0001209191-20-011796 · doc4.xml · nonDerivative · entry 4 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,283,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 00:24 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionStock Option (right to buy) · Derivative | 63,340 | Not disclosed Strike: $14.31 | Not disclosed |
DisclosureSEC source: 0001209191-20-011796 · doc4.xml · derivative · entry 7 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,223 Underlying: Common Stock · 63,340 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: As of February 19, 2020, and prior to this transaction, the exercised options were fully vested. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 00:24 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 7,723 | $51.14 | $394,977.39 |
DisclosureSEC source: 0001209191-20-011796 · doc4.xml · nonDerivative · entry 3 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268,557 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $50.99 to $51.36 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 00:24 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 55,617 | $50.41 | $2,803,536.17 |
DisclosureSEC source: 0001209191-20-011796 · doc4.xml · nonDerivative · entry 2 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,276,280 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $49.99 to $50.97 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 00:24 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 63,340 | $14.31 | $906,395.40 |
DisclosureSEC source: 0001209191-20-011796 · doc4.xml · nonDerivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,331,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 23:51 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionStock Option (right to buy) · Derivative | 119,525 | Not disclosed Strike: $14.31 | Not disclosed |
DisclosureSEC source: 0001209191-20-007294 · doc4.xml · derivative · entry 3 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,563 Underlying: Common Stock · 119,525 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: As of February 4, 2020, and prior to this transaction, the exercised options were fully vested. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 23:51 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 119,525 | $45.18 | $5,400,701.27 |
DisclosureSEC source: 0001209191-20-007294 · doc4.xml · nonDerivative · entry 2 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268,557 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $44.99 to $45.61 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 23:51 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 119,525 | $14.31 | $1,710,402.75 |
DisclosureSEC source: 0001209191-20-007294 · doc4.xml · nonDerivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,388,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2020 Filed Jan 18, 2020 00:55 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionStock Option (right to buy) · Derivative | 105,735 | Not disclosed Strike: $10.27 | Not disclosed |
DisclosureSEC source: 0001209191-20-004185 · doc4.xml · derivative · entry 7 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,948 Underlying: Common Stock · 105,735 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: As of January 16, 2020, and prior to this transaction, the exercised options were fully vested. Read SEC document |
| January 17, 2020 Filed Jan 18, 2020 00:55 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 22,179 | $42.13 | $934,399.05 |
DisclosureSEC source: 0001209191-20-004185 · doc4.xml · nonDerivative · entry 5 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268,557 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $42.00 to $42.39 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 17, 2020 Filed Jan 18, 2020 00:55 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 83,556 | $41.46 | $3,463,872.47 |
DisclosureSEC source: 0001209191-20-004185 · doc4.xml · nonDerivative · entry 4 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,290,736 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $40.99 to $41.98 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 17, 2020 Filed Jan 18, 2020 00:55 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 105,735 | $10.27 | $1,085,898.45 |
DisclosureSEC source: 0001209191-20-004185 · doc4.xml · nonDerivative · entry 3 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,374,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2020 Filed Jan 18, 2020 00:55 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionStock Option (right to buy) · Derivative | 30,317 | Not disclosed Strike: $10.27 | Not disclosed |
DisclosureSEC source: 0001209191-20-004185 · doc4.xml · derivative · entry 6 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,683 Underlying: Common Stock · 30,317 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: As of January 16, 2020, and prior to this transaction, the exercised options were fully vested. Read SEC document |
| January 16, 2020 Filed Jan 18, 2020 00:55 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | SaleCommon Stock | 30,317 | $41.01 | $1,243,169.81 |
DisclosureSEC source: 0001209191-20-004185 · doc4.xml · nonDerivative · entry 2 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268,557 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $40.99 to $41.09 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.